CN113164608A - 抗病毒剂 - Google Patents

抗病毒剂 Download PDF

Info

Publication number
CN113164608A
CN113164608A CN202180000841.0A CN202180000841A CN113164608A CN 113164608 A CN113164608 A CN 113164608A CN 202180000841 A CN202180000841 A CN 202180000841A CN 113164608 A CN113164608 A CN 113164608A
Authority
CN
China
Prior art keywords
antiviral agent
active oxygen
xanthine oxidase
xanthine
oxidase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180000841.0A
Other languages
English (en)
Chinese (zh)
Inventor
西野武士
草野辉男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genjin Life Sciences Co ltd
Genjin Science And Culture Contract Society
Nippon Medical School Foundation
Original Assignee
Genjin Life Sciences Co ltd
Genjin Science And Culture Contract Society
Nippon Medical School Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genjin Life Sciences Co ltd, Genjin Science And Culture Contract Society, Nippon Medical School Foundation filed Critical Genjin Life Sciences Co ltd
Publication of CN113164608A publication Critical patent/CN113164608A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180000841.0A 2021-02-02 2021-02-02 抗病毒剂 Pending CN113164608A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/003756 WO2022168169A1 (ja) 2021-02-02 2021-02-02 抗ウイルス剤

Publications (1)

Publication Number Publication Date
CN113164608A true CN113164608A (zh) 2021-07-23

Family

ID=76875998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180000841.0A Pending CN113164608A (zh) 2021-02-02 2021-02-02 抗病毒剂

Country Status (5)

Country Link
US (1) US20240115570A1 (https=)
EP (1) EP4289444A1 (https=)
JP (1) JPWO2022168169A1 (https=)
CN (1) CN113164608A (https=)
WO (1) WO2022168169A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110699A (ja) * 1995-10-12 1997-04-28 Senju Pharmaceut Co Ltd 抗ウイルス剤
US20160151469A1 (en) * 2014-11-30 2016-06-02 Regen BioPharma, Inc. Immune modulation by tlr activation for treatment of filovirus infections including ebola
US20180015153A1 (en) * 2016-07-16 2018-01-18 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
CN108135964A (zh) * 2015-06-19 2018-06-08 分子防御公司 谷胱甘肽制剂和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957901B1 (en) * 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
CA2467240A1 (en) * 2001-11-16 2003-05-30 The Uab Research Foundation Xanthine oxidase inhibition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110699A (ja) * 1995-10-12 1997-04-28 Senju Pharmaceut Co Ltd 抗ウイルス剤
US20160151469A1 (en) * 2014-11-30 2016-06-02 Regen BioPharma, Inc. Immune modulation by tlr activation for treatment of filovirus infections including ebola
CN108135964A (zh) * 2015-06-19 2018-06-08 分子防御公司 谷胱甘肽制剂和使用方法
US20180015153A1 (en) * 2016-07-16 2018-01-18 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NARJES SAHEB SHARIF-ASKARI,ET AL.: "Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue", 《CLINICAL AND TRANSLATIONAL SCIENCE》 *
韩娜等: "SOD与别嘌呤醇对流感病毒感染致小鼠病损的保护作用", 《中国药理学通报》 *

Also Published As

Publication number Publication date
JPWO2022168169A1 (https=) 2022-08-11
US20240115570A1 (en) 2024-04-11
EP4289444A1 (en) 2023-12-13
WO2022168169A1 (ja) 2022-08-11

Similar Documents

Publication Publication Date Title
Cho et al. Periodontal wound healing and tissue regeneration: a narrative review
On et al. Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches
US7740831B2 (en) Compositions for potentiating glutathione
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
ES2243941T3 (es) Metodo multi-facetico para reprimir la reproduccion de virus latentes en humanos y animales.
JP2005529938A (ja) 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
CN101115505A (zh) 治疗由过氧亚硝酸盐过度表达引起的哺乳动物疾病和创伤的方法和组合物
AU3308999A (en) L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
Janik-Hazuka et al. Hyaluronic acid-based nanocapsules as efficient delivery systems of garlic oil active components with anticancer activity
JP2019500386A (ja) メチオニン及びアスパラギンの枯渇を利用してヒトをはじめとする哺乳動物を癌に対して処置する方法
Cotgreave et al. Glutathione and protein function
JPS62246520A (ja) 白内障の予防及び逆転方法及び眼の組成物
KR20200063275A (ko) 코로나바이러스 예방 및 치료제
Locci et al. Current uses of bromelain in children: a narrative review
CN116887852A (zh) 干细胞启动组合物及启动的干细胞
ES2926725T3 (es) Formulación médica para tratar la hipercolesterolemia
CN113164608A (zh) 抗病毒剂
BR0308576A (pt) Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero
Feng et al. Hyperbaric oxygen therapy for the treatment of bone-related diseases
CN101288675A (zh) 一种治疗心脑血管类疾病的药物及其生产方法
Hoshikawa et al. In vitro and in vivo effects of D-allose: up-regulation of thioredoxin-interacting protein in head and neck cancer cells
EP2497488B1 (en) Method for treating delayed-type hypersensitivity reactions associated with changes of qualitative and/quantitative composition of blood extracellular DNA
CA2492368A1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
US11278514B2 (en) Composition compromising dunnione as effective ingredient for prevention or alleviation of hair loss
Turkyilmaz et al. Protecting effect of vitamin U against amiodarone-induced hepatic damage via its antioxidative activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination